Back to top

Image: Bigstock

QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration

Read MoreHide Full Article

Key Takeaways

  • QuantumScape, Civeo and Agenus are highlighted for notable earnings acceleration this month.
  • Each company showed rising quarter-over-quarter EPS growth and strong projected future increases.
  • QS expects 17% earnings growth, CVEO 69.8%, and AGEN leads with a projected 114.7% increase this year.

Top executives and analysts focus on consistent earnings growth, which reflects a company’s profitability. However, earnings acceleration has an even greater impact on driving up stock prices. Studies show that successful stocks experience a speed-up in earnings before their stock prices increase.

To that end, QuantumScape Corporation (QS - Free Report) , Civeo Corporation (CVEO - Free Report) and Agenus Inc. (AGEN - Free Report) are exhibiting strong earnings acceleration this month.

What is Earnings Acceleration?

Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if a company’s quarter-over-quarter earnings growth rate increases within a stipulated time frame, it can be called earnings acceleration.

In the case of earnings growth, you pay for something that is already reflected in the stock price. However, earnings acceleration helps spot stocks that haven’t yet caught the attention of investors and, once secured, will invariably lead to a rally in the share price. This is because earnings acceleration considers both the direction and magnitude of growth rates.

An increasing percentage of earnings growth means that the company is fundamentally sound and has been on the right track for a considerable period. Meanwhile, a sideways percentage of earnings growth indicates a period of consolidation or slowdown, while a decelerating percentage of earnings growth may drag prices down.

Screening Parameters Using Research Wizard:

Look at stocks for which the last two quarter-over-quarter percentage earnings per share (EPS) growth rates exceed the previous periods’ growth rates. The projected EPS growth rates for the upcoming quarter are expected to exceed those of prior periods.

EPS % Projected Growth (Q1)/(Q0) greater than EPS % Growth (Q0)/(Q-1): The projected growth rate for the current quarter (Q1) over the completed quarter (Q0) has to be greater than the growth rate from the completed quarter (Q0) over one quarter ago (Q-1).

EPS % Growth (Q0)/(Q-1) greater than EPS % Growth (Q-1)/(Q-2): The growth rate for the completed quarter (Q0) over one quarter ago (Q-1) has to be greater than the growth rate from one quarter ago (Q-1) over two quarters ago (Q-2).

EPS % Growth (Q-1)/(Q-2) greater than EPS % Growth (Q-2)/(Q-3): The growth rate from one quarter ago (Q-1) over two quarters ago (Q-2) has to be greater than the growth rate from two quarters ago (Q-2) over three quarters ago (Q-3).

In addition to this, we have added the following parameters:

Current Price greater than or equal to $5: This screens out low-priced stocks.

Average 20-day volume greater than or equal to 50,000: High trading volume implies that the stocks have adequate liquidity.

The above criteria narrowed the universe of around 7,735 stocks to only four. Here are the top three stocks:

QuantumScape Corporation

QuantumScape develops solid-state lithium-metal batteries for electric vehicles in the United States. QuantumScape has a Zacks Rank #2 (Buy). QuantumScape’s expected earnings growth rate for the current year is 17% (read more: QuantumScape Vs. NVIDIA: Which Stock Is a Better Buy Now?).

Civeo Corporation

Civeo provides hospitality services for the natural resource industry globally. Civeo has a Zacks Rank #2. CVEO’s expected earnings growth rate for the current year is 69.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Agenus

Agenus is a clinical-stage biotechnology company that develops therapies to activate immune responses against cancer globally. Agenus has a Zacks Rank #2. AGEN’s expected earnings growth rate for the current year is 114.7%.

You can sign up now for your 2-week free trial to the Research Wizard and start using this screen in your trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Agenus Inc. (AGEN) - free report >>

Civeo Corporation (CVEO) - free report >>

QuantumScape Corporation (QS) - free report >>

Published in